DUBLIN, May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts.A subgroup analysis selected as a platform presentation focused on patients with Multiple System Atrophy (MSA ...

Acquisition expands MSA's Detection solutions and adds new capabilities in the gas analysis and process safety markets With annual revenue of approximately $55 million, M&C TechGroup is highly complementary to MSA's technology, customer base and distribution network Transaction expected to be accretive to MSA's adjusted earnings in 2025PITTSBURGH, May 7, 2025 /PRNewswire/ --Global safety equipment and solutions provider MSA Safety Incorporated (NYSE: MSA) today announced it has acquired M&C TechGroup in a ...

Financial Performance - Net sales for Q1 2025 were $421,340,000, a 1.3% increase from $413,302,000 in Q1 2024[7] - Gross profit for Q1 2025 was $193,395,000, down 0.6% from $195,531,000 in Q1 2024[7] - Operating income decreased to $77,761,000 in Q1 2025 from $80,112,000 in Q1 2024, reflecting a decline of 2.9%[7] - Net income for Q1 2025 was $59,605,000, compared to $58,139,000 in Q1 2024, representing a 2.5% increase[7] - Earnings per share attributable to common shareholders increased to $1.51 in Q1 2025 from $1.48 in Q1 2024[7] - Comprehensive income for Q1 2025 was $82,343,000, significantly higher than $47,840,000 in Q1 2024, indicating a substantial increase[11] - Adjusted operating income for Q1 2025 was $87,502 thousand, slightly down from $88,009 thousand in Q1 2024, reflecting a decrease of 0.6%[53] - Basic earnings per share for Q1 2025 were $1.51, an increase from $1.48 in Q1 2024[55] - The Fire Service product group generated $150,616 thousand in sales, accounting for 36% of total consolidated sales in Q1 2025[53] - The Americas segment generated net sales of $293.16 million, while the International segment contributed $128.18 million for Q1 2025[52] Assets and Liabilities - Total assets as of March 31, 2025, were $2,235,885,000, up from $2,205,784,000 at the end of 2024[13] - Total liabilities decreased to $1,045,740,000 as of March 31, 2025, from $1,062,465,000 at the end of 2024[13] - Total assets as of March 31, 2025, amounted to $2,235,885 thousand, compared to $2,174,330 thousand at the end of Q1 2024, indicating a growth of 2.8%[52] - The company’s total liabilities decreased to $1.05 billion as of March 31, 2025, from $1.06 billion at the end of 2024, a reduction of 1.2%[14] - As of March 31, 2025, the company's total long-term debt was $502.1 million, a decrease from $508.0 million as of December 31, 2024[66] Cash Flow and Dividends - Cash flow from operating activities for Q1 2025 was $61,833,000, compared to $50,886,000 in Q1 2024, showing a 21.5% increase[16] - The company paid dividends of $0.51 per common share in Q1 2025, up from $0.47 per share in Q1 2024[7] - Common dividends declared were $20,023,000 for the quarter ended March 31, 2025, compared to $18,480,000 for the same period in 2024, representing an increase of 8.4%[19] Inventory and Capital Expenditures - Total inventories increased to $306.675 million as of March 31, 2025, up from $296.796 million at December 31, 2024, reflecting a growth in finished products and raw materials[41] - Capital expenditures for Q1 2025 totaled $10,784 thousand, compared to $11,219 thousand in Q1 2024, representing a decrease of 3.9%[52] Restructuring and Charges - The company recorded restructuring charges of $1.9 million for the three months ended March 31, 2025, compared to $3.0 million for the same period in 2024, indicating a reduction in restructuring efforts[38][39] - The company’s total restructuring reserves decreased to $4.4 million as of March 31, 2025, from $9.8 million at December 31, 2023[40] Tax and Compliance - The effective tax rate for Q1 2025 was 23.5%, up from 23.1% in Q1 2024, primarily due to state income taxes[56] - As of March 31, 2025, the Company was in full compliance with the restrictive covenants under its various credit agreements[74] Foreign Currency and Derivatives - The notional amount of open foreign currency forward contracts was $150.7 million as of March 31, 2025, down from $184.0 million at December 31, 2024[79] - The company reported currency exchange losses of $2.6 million for the three months ended March 31, 2025, compared to gains of $1.8 million in the same period of 2024[81] Product Liability and Legal Matters - The company faces ongoing product liability claims related to PFAS substances, with 731 lawsuits involving 9,274 claims as of April 22, 2025[90] - The company established reserves for single incident product liability claims based on historical experience and expected settlement costs[85] - The company expects to continue pursuing insurance coverage and indemnification related to ongoing litigation[90]

MSA Safety (MSA) Q1 2025 Earnings Call April 30, 2025 10:00 AM ET Company Participants Larry De Maria - Executive Director, Investor RelationsSteven Blanco - President & CEOElyse Brody - Interim CFO Conference Call Participants Rob Mason - Senior Research AnalystRoss Sparenblek - Equity Research AnalystJeff Van Sinderen - Senior AnalystMichael Shlisky - Managing Director & Senior Equity Research Analyst Operator Good day, and welcome to the MSA Safety First Quarter twenty twenty five Earnings Conference Cal ...

MSA Safety (MSA) Q1 2025 Earnings Call April 30, 2025 10:00 AM ET Speaker0 Good day, and welcome to the MSA Safety First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Larry De Maria. Please go ahead. Speaker1 Thank you. Good morning and welcome to MSA Safety's first quarter twenty twenty five earnings conference call. This is Larry De Maria, Executive Director of Inv ...

First Quarter 2025 Earnings Presentation April 30, 2025 Non-GAAP Financials To supplement our Consolidated Financial Statements presented in accordance with generally accepted accounting principles ("GAAP"), we use, and this presentation includes, certain non-GAAP financial measures. These financial measures include organic sales change, adjusted operating income, adjusted operating margin, adjusted EBITDA, adjusted EBITDA margin, adjusted earnings, adjusted earnings per diluted share, R&D investment, net d ...

MSA Safety (MSA) came out with quarterly earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.61 per share a year ago. These figures are adjusted for non- recurring items. MSA Safety shares have lost about 7.9% since the beginning of the year versus the S&P 500's decline of -6%. This quarterly report represents an earnings surprise of 5.66%. A quarter ago, it was expected that this maker of safety products would post earnings of $2.22 per shar ...

EXHIBIT 99.1 FOR IMMEDIATE RELEASE FROM: MSA Safety Incorporated Ticker: MSA (NYSE) Media Relations Contact: Mark Deasy (412) 559-8154 Investor Relations Contact: Larry De Maria (917) 449-2237 MSA Safety Announces First Quarter 2025 Results First Quarter 2025 Highlights PITTSBURGH, April 29, 2025 - Global safety equipment and solutions provider MSA Safety Incorporated (NYSE: MSA) today reported financial results for the first quarter of 2025. "Our solid first quarter results demonstrate the team's continued ...

First Quarter 2025 Highlights Achieved quarterly net sales of $421 million, a 2% GAAP increase and 4% organic(a) increase year-over-year Generated GAAP operating income of $78 million, or 18.5% of sales, and adjusted operating income of $88 million, or 20.8% of sales Recorded GAAP net income of $60 million, or $1.51 per diluted share, and adjusted earnings of $66 million, or $1.68 per diluted share Returned capital to shareholders through $20 million of dividends and $10 million of share repurchases, invest ...

DUBLIN, April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place May 9-11, 2025, in Boston, Massachusetts.  These analyses support the Company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension ( ...